📄 cardiovascular medicine

Renal Outcomes of Staged Versus Concomitant Percutaneous Coronary Intervention and Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis of 7,119 patients found that while staged percutaneous coronary intervention (PCI) prior to transcatheter aortic valve replacement (TAVR) does not significantly reduce the overall risk of contrast-induced acute kidney injury compared to concomitant PCI, it may offer a protective benefit against severe (stage 3/4) kidney injury.

Original authors: Chanda, V., Bittar, V., Carvalho, P., Garot, P.

Published 2026-07-21

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Chanda, V., Bittar, V., Carvalho, P., Garot, P.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine your body as a bustling city where the heart is the central power plant and the kidneys are the sophisticated water treatment facilities. Sometimes, the power plant gets clogged with rust (a condition called coronary artery disease), and the main valve that lets water flow out gets stuck shut (aortic stenosis). To fix these problems, doctors have developed two amazing, minimally invasive tools: a tiny balloon and stent to unclog the pipes (Percutaneous Coronary Intervention, or PCI) and a special delivery system to swap out the stuck valve without opening the chest (Transcatheter Aortic Valve Replacement, or TAVR).

Here's the tricky part: both of these tools require a special "dye" (contrast media) to help the doctors see inside the pipes and valves on X-ray screens. This dye is like a high-powered cleaning solvent that works great for the cameras, but it can be a bit harsh on the water treatment plant (the kidneys). If the kidneys get overwhelmed by too much dye at once, they can get sick, leading to a condition called contrast-induced acute kidney injury (CI-AKI). The big question for doctors has been: Is it better to fix the pipes and the valve in one giant marathon session, or should they take a break and do them in two separate sprints? This paper dives into that exact timing question to see which approach keeps the kidneys happiest.

The Great Kidney Timing Debate

In this study, the researchers acted like detectives, gathering clues from 11 different investigations involving 7,119 patients. They wanted to solve the mystery of whether doing the two procedures together (concomitant) or splitting them up (staged) was better for the kidneys. Think of it like deciding whether to eat a massive buffet in one sitting or to have a light lunch and a lighter dinner. Does splitting the meal protect your stomach, or does it not matter?

The team used a powerful statistical magnifying glass (a meta-analysis) to combine all the data. Their first big discovery was a bit of a surprise: for the most common, mild cases of kidney stress (Stage 1 and Stage 2), it didn't really matter which way you did it. Whether the patients had the procedures done all at once or split up, the odds of getting a mild kidney bump were essentially the same. The data showed an odds ratio of 1.02, which is basically a fancy way of saying "no difference." Even for the slightly more serious Stage 2 issues, the results were a toss-up, with an odds ratio of 1.01.

However, the story changes when we look at the heavy hitters. When the researchers zoomed in on the most severe kidney injuries (Stage 3 and 4), a clear pattern emerged. They found that patients who had their procedures split up (the staged approach) had significantly better outcomes. The odds of suffering a severe kidney injury were cut almost in half for the staged group compared to the group that did everything at once. The numbers showed an odds ratio of 0.48, meaning the staged approach was the clear winner for protecting the kidneys from the worst-case scenarios.

But here is the catch: the authors are careful not to declare this a solved mystery. They point out that the studies they looked at were mostly observational, meaning they watched what happened in real life rather than running a controlled experiment where they forced some people to do one method and others to do the other. Because of this, there is still some uncertainty, and the results for the severe cases, while statistically significant, came with a wide range of possibilities. The authors suggest that while splitting the procedures seems like a smart move for patients who already have weak kidneys or are at high risk, we still need large-scale, randomized trials to be 100% sure.

So, what's the takeaway? If you are a patient with a clogged pipe and a stuck valve, and your kidneys are already a bit fragile, the evidence suggests that taking a breather between the two procedures might be the safer bet to avoid a severe kidney scare. But for the average patient, the choice might not make a huge difference for mild issues. The doctors are still waiting for the final, definitive proof, but for now, splitting the work seems to offer a little extra shield for the most vulnerable kidneys.

Technical Summary: Renal Outcomes of Staged Versus Concomitant Percutaneous Coronary Intervention and Transcatheter Aortic Valve Replacement

Problem Statement
Patients with severe aortic stenosis (AS) frequently present with concurrent coronary artery disease (CAD), with nearly half of those undergoing aortic valve intervention having comorbid CAD. The optimal timing for managing CAD in these patients—specifically whether to perform percutaneous coronary intervention (PCI) before transcatheter aortic valve replacement (TAVR) in a "staged" approach or simultaneously in a "concomitant" approach—remains a subject of clinical debate. While both procedures involve the administration of contrast media, posing a risk for contrast-induced acute kidney injury (CI-AKI), existing literature offers conflicting perspectives. Some studies suggest staged procedures reduce renal risk by splitting contrast exposure, while others find no significant difference. Furthermore, prior meta-analyses have yielded inconsistent results regarding renal outcomes, and large-scale randomized controlled trials (RCTs) comparing these timing strategies are currently lacking. This study aims to resolve these inconsistencies by systematically comparing the incidence and severity of CI-AKI between staged and concomitant PCI-TAVR strategies.

Methodology
The authors conducted a systematic review and meta-analysis adhering to the PRISMA guidelines and the Cochrane Collaboration Handbook. The study protocol was registered with PROSPERO.

Data Sources: A comprehensive search of MEDLINE, Embase, and the Cochrane Library was performed (search date: May 5, 2026).
Eligibility Criteria: The review included peer-reviewed full-text publications involving adult patients (>18 years) with severe AS and CAD undergoing both PCI and TAVR. Studies were required to report post-procedural renal outcomes separately for staged and concomitant strategies.
Study Selection: Eleven retrospective observational studies comprising 7,119 patients were included.
Statistical Analysis: A random-effects model was used to calculate odds ratios (OR) with 95% confidence intervals (CI) for the incidence of CI-AKI. Outcomes were stratified by AKI severity stages (Overall, Stage 1, Stage 2, and Stage 3/4). Heterogeneity was assessed using $I^2$ statistics, and sensitivity analyses (leave-one-out) were performed to validate robustness. Publication bias was evaluated via funnel plots and Egger's regression test. The methodological quality of included studies was assessed using the ROBINS-I tool.

Key Contributions and Results
The meta-analysis provides a nuanced assessment of renal outcomes based on the severity of kidney injury:

Overall CI-AKI: There was no statistically significant difference in the overall incidence of CI-AKI between staged and concomitant approaches (OR 1.02; 95% CI 0.53 to 1.98; p = 0.959).
Mild to Moderate Injury (Stage 1 & 2): Subgroup analyses revealed no significant differences for Stage 1 CI-AKI (OR 1.99; 95% CI 0.38 to 10.47; p = 0.417) or Stage 2 CI-AKI (OR 1.01; 95% CI 0.39 to 2.64; p = 0.978).
Severe Injury (Stage 3/4): A statistically significant difference emerged favoring the staged approach for severe kidney injury. Patients undergoing staged procedures had significantly lower odds of developing Stage 3/4 CI-AKI compared to those undergoing concomitant procedures (OR 0.48; 95% CI 0.24 to 0.99; p = 0.046).
Heterogeneity and Bias: The study noted moderate to high heterogeneity across outcomes, largely attributed to variations in AKI definitions (RIFLE vs. AKIN criteria) and patient characteristics. Sensitivity analysis indicated that omitting the Venturi et al. study adjusted the overall AKI endpoint OR to 0.24, highlighting the influence of specific datasets. Publication bias was suggested for Stage 2/3 and Stage 3/4 outcomes.

Significance and Claims
The paper claims that while a staged PCI approach does not universally reduce the risk of CI-AKI across all severity levels, it offers a potential protective benefit specifically against severe renal impairment (Stage 3/4). The authors posit that splitting contrast exposure may be particularly beneficial for patients with pre-existing renal vulnerabilities or significant baseline renal impairment, who are at higher risk for severe sequelae.

The study emphasizes that current clinical guidelines lack definitive evidence from RCTs regarding procedural timing. Consequently, the authors recommend a staged approach for patients with CAD and AS who have significant pre-existing renal impairment or are at high risk for AKI. They conclude that while the staged strategy appears safer for severe outcomes, the decision must be individualized, considering factors such as lesion complexity, symptomatology, and the ability to tolerate dual antiplatelet therapy. The authors explicitly state that large-scale, multi-center randomized controlled trials are essential to establish a definitive relationship between procedural timing and renal outcomes, as the current evidence is derived from observational data with inherent limitations.

More like this